Forgot Password?
Return to Course Listing

CME: Novel and practical approaches to the prevention of neutropenia associated with myelosuppressive chemotherapy (NON-ACCREDITED)


Activity Description / Statement of Need:

In this online, self-learning activity:

Neutropenia, a decrease in the number of a type of white blood cell (WBC) in the body, is a common complication in patients undergoing myelosuppressive chemotherapy that can result in serious, life-threatening infections. Febrile neutropenia (FN), or neutropenia accompanied by a fever, poses an even greater risk to patients and the frequent treatment complication results in over 100,000 hospitalizations in the U.S. each year. Neutropenia can manifest up to twelve days following treatment with a chemotherapy agent and FN occurs in about eight per 1,000 patients receiving chemotherapy. Fever is defined as a single oral temperature of 38.3+ °C or 38.0+ °C over the course of an hour, with neutropenia defined as less than 500 neutrophils/mcL or less than 1000 with a predicted decline to less 500 over the following 48 hours. Development of FN may lead to hospitalization with costs estimated at approximately $15,000 per visit, and it may also complicate care by reducing chemotherapy relative dose intensity (RDI) and possibly compromise treatment efficacy and lower survival rates.

Target Audience:

Oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other HCPs with an interest in or who clinically encounter patients with FN or at risk of developing it.

Commercial Support Disclosure: This program is supported by educational grants from Coherus Biosciences and Mylan Inc., a Viatris company.

This activity is free of charge.

Release Date: September 20, 2022 -- Expiration Date: September 20, 2023

Faculty: Eric Tam, MD


Faculty introduction, disclosures

Chemotherapy-associated FN: defining the problem

  • Epidemiology
  • Impact of FN on chemotherapy RDI and patient outcomes
  • FN risk assessment tools, their limitations, and their place in treatment decision-making

Addressing the problem of FN associated with myelosuppressive chemotherapy

  • Present prophylactic and treatment approaches: clinical evidence summary

-  Primary prophylaxis

-  Secondary prophylaxis

-  Therapeutic use in patients with FN and neutropenia without fever

-  Roles of CSFs, biosimilar agents

-  Dosing and timing, including long-acting agent considerations

-  Cyclin-dependent kinases 4/6 inhibitors and their myeloprotective role in select diseases

  • Real-world evidence and barriers to care

-  Treatment persistence

-  Pandemic-related considerations

  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the impact of FN on chemotherapy RDI and patient outcomes.
  • Describe the role, utility, and limitations of FN risk assessment tools.
  • Identify barriers to prevention of FN and how presently available CSF and myeloprotective treatments address them.
  • Formulate a treatment plan for a patient at a high risk of developing chemotherapy-associated FN.



Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Eric Tam, MD, Assistant Professor, Keck Medicine of University of Southern California, has received financial compensation from Maximus, Inc. for consulting work.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

Commercial Support Disclosure: This program is supported by educational grants from Mylan Inc., a Viatris company, and Coherus Biosciences.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 0% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Biosimilars in the treatment of malignancies and supportive care

At the cutting edge of treatment for advanced diffuse large B-cell lymphoma (DLBCL): Updates in medical management and individualizing patient care

Advances in Treating HER2-Postive Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies

Metastatic colorectal cancer (mCRC) treatment: Therapeutic updates, best practices, and barriers to care